Entos Pharmaceuticals Inc.
$5,200,000.00 CAD
- Department
- National Research Council Canada
- Recipient country
- Canada
- Fiscal year
- 2021-2022
- Agreement period
- November 1, 2021 – December 31, 2022
- Reference
- nrc-cnrc:172-2021-2022-Q3-981653
Published purpose
Entos has developed Covigenix VAX-001, a DNA Proteo-Lipid Vehicle (PLV) vaccine intended for the prevention of COVID-19 infection by SARS-CoV-2. In this project, Entos will advance the VAX-001 vaccine candidate through Phase 2 clinical trials to establish its safety and immunogenicity in healthy adults.
In plain English AI-generated
This grant supports Entos Pharmaceuticals in advancing its COVID-19 DNA vaccine candidate through Phase 2 clinical trials to assess safety and immune response in healthy adults.
Category: Health Primarily funds activity in Canada
Based on the published description. See how AI categorization works — the linked official record is authoritative.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.